Array Biopharma Inc (ARRY) 8.05 $ARRY
Oncolytics Seeks Orphan Drug Status for Reolysin in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:59PM CST
Oncolytics Biotech Inc. (ONCY) announced that it has submitted an application to FDA for obtaining orphan drug designation for Reolysin for the treatment of high-grade gliomas (HGG) in pediatric patients.
AGN: 229.49 (+1.87), BIIB: 391.66 (-0.45), ONCY: 0.51 (+0.02), ARRY: 8.05 (+0.08)
Why Array BioPharma Inc. Shares Skyrocketed 51% in January
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 06, 6:35AM CST
ARRY data by YCharts What: Shares of Array BioPharma , a biopharmaceutical company that's focused on developing novel drugs to fight cancer, skyrocketed by 51% in January, based on data from S&P Capital IQ , after announcing a pipeline...
NVS: 102.20 (-0.17), ARRY: 8.05 (+0.08)
Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
PR Newswire - Thu Feb 05, 11:30AM CST
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Leerink Swann Healthcare Conference in New York. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
ARRY: 8.05 (+0.08)
Array BioPharma's (ARRY) CEO Ron Squarer on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 03, 3:25PM CST
ARRY: 8.05 (+0.08)
Array BioPharma (ARRY) Q2 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Feb 03, 7:55AM CST
ARRY: 8.05 (+0.08)
Array BioPharma beats by $0.12, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 7:02AM CST
ARRY: 8.05 (+0.08)
Array Biopharma Reports Financial Results For The Second Quarter Of Fiscal 2015
PR Newswire - Tue Feb 03, 7:00AM CST
Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the second quarter of its fiscal year ending June 30, 2015.
ARRY: 8.05 (+0.08), NVS: 102.20 (-0.17)
Notable earnings before Tuesday’s open
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 4:30PM CST
CEVA: 19.65 (+0.04), HCLP: 37.88 (+0.99), PNR: 66.87 (+1.09), AET: 96.12 (-0.96), HW: 15.96 (+0.10), UPS: 101.79 (+0.38), NOV: 53.36 (+0.80), JLL: 161.15 (+0.18), ST: 52.50 (+0.01), LYB: 89.99 (+0.19), ACI: 1.19 (+0.02), R: 93.92 (+0.41), TECH: 94.61 (+1.83), SPR: 49.35 (+0.47), BP: 41.93 (+0.59), NYT: 14.45 (+0.28), WDR: 49.94 (+0.15), HRC: 46.88 (+0.14), MNK: 115.01 (+2.51), SC: 22.11 (+0.38), CHD: 84.03 (+0.67), ETN: 72.55 (+0.90), BHE: 22.89 (+0.03), ARG: 115.27 (+1.28), AGCO: 49.78 (+0.97), EMR: 58.68 (+0.08), GLPI: 33.57 (-0.56), CNC: 118.18 (-0.01), HCA: 68.54 (-0.48), MHO: 21.20 (-0.27), CARB: 14.96 (+0.07), AXE: 76.07 (+0.44), IMS: 25.68 (+0.22), GCI: 34.77 (-0.07), LPT: 39.14 (-0.05), CBR: 4.05 (+0.04), ARRY: 8.05 (+0.08), AN: 63.70 (+0.23)
Uptrend Call Working As Array Biopharma Stock Rises 93.5% (ARRY)
Comtex SmarTrend(R) - Mon Feb 02, 9:09AM CST
SmarTrend identified an Uptrend for Array Biopharma (NASDAQ:ARRY) on October 28th, 2014 at $3.71. In approximately 3 months, Array Biopharma has returned 93.52% as of today's recent price of $7.17.
ARRY: 8.05 (+0.08)
'Mad Money' Lightning Round: Alliant Techsystems Is Fabulous
at The Street - Fri Jan 30, 5:00AM CST
Cramer prefers Garmin to Trimble Navigation and recommends Kohlberg Kravis Roberts and Blackstone Group.
LMT: 196.95 (-0.53), BX: 37.40 (+0.49), TRMB: 26.86 (-0.40), NOC: 167.14 (-0.15), GRMN: 55.93 (+0.02), PPC: 26.75 (+0.77), JDSU: 13.26 (+0.23), TSN: 40.70 (-0.09), KKR: 24.42 (+0.06), ATK: 140.03 (+0.78), ARRY: 8.05 (+0.08)
Defense Stocks Are Fabulous - Cramer's Lightning Round (1/29/15)
SA Editor Mohit Manghnani - Seeking Alpha - Fri Jan 30, 4:30AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, January 29. Bullish Calls: Trimble Navigation (NASDAQ: TRMB ): "I do prefer Garmin (NASDAQ: GRMN ) if you want to be in that game." KKR...
LMT: 196.95 (-0.53), BX: 37.40 (+0.49), TRMB: 26.86 (-0.40), MDCO: 29.79 (+0.91), NOC: 167.14 (-0.15), GRMN: 55.93 (+0.02), JDSU: 13.26 (+0.23), PPC: 26.75 (+0.77), TSN: 40.70 (-0.09), KKR: 24.42 (+0.06), ATK: 140.03 (+0.78), MTW: 21.86 (+0.34), ARRY: 8.05 (+0.08)
Jim Cramer's 'Mad Money' Recap: The Bears Retreat and the Market Celebrates
at The Street - Thu Jan 29, 7:19PM CST
Today was a terrific snap-back rally, a day when the bears retreated and calmer heads could take advantage of all the positives that go unappreciated on most days, Cramer says.
LMT: 196.95 (-0.53), BX: 37.40 (+0.49), FB: 75.74 (-0.49), NOC: 167.14 (-0.15), GRMN: 55.93 (+0.02), TSN: 40.70 (-0.09), KKR: 24.42 (+0.06), ATK: 140.03 (+0.78), BA: 149.73 (+1.64), CLB: 112.18 (+3.65), SBUX: 91.58 (-0.24), RDUS: 50.37 (+0.63), TRMB: 26.86 (-0.40), PHM: 22.89 (+0.02), PPC: 26.75 (+0.77), JDSU: 13.26 (+0.23), MCD: 95.65 (+0.56), ARRY: 8.05 (+0.08)
Earnings Peek: Array BioPharma Has A Lot Going On, And A Lot Of Money
Clinically Sound Investor - at Seeking Alpha - Wed Jan 28, 9:18AM CST
ARRY: 8.05 (+0.08)
Does This 50% Price Target Hike For Array BioPharma Inc. Make Sense?
Sean Williams, The Motley Fool - Motley Fool - Tue Jan 27, 8:51AM CST
What: Shares of Array BioPharma , a biopharmaceutical company focused on developing novel small molecule cancer drugs, surged just shy of 10% on Monday following a hefty price target hike from brokerage firm Stifel Nicolaus. So what: Stifel...
NVS: 102.20 (-0.17), ARRY: 8.05 (+0.08)
Array BioPharma (ARRY) Jumps: Stock Adds 9.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 27, 7:51AM CST
Array BioPharma, Inc. (ARRY) was a big mover last session, as the company saw its shares rise by almost 10% on the day.
AMAG: 41.49 (+0.23), ARRY: 8.05 (+0.08)
Biotech Stocks Technical Analysis - Achillion Pharma, Array BioPharma, Rexahn Pharma, Neurocrine Biosciences, and Bluebird Bio
PR Newswire - Tue Jan 27, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Array BioPharma Inc. (NASDAQ: ARRY), Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Bluebird Bio Inc. (NASDAQ: BLUE). Free research report on Achillion Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=Achillion...amp;s=ACHN. On Monday, January 26, 2015, the NASDAQ Composite ended at 4,771.76, up 0.29%, the Dow Jones Industrial Average advanced 0.03%, to finish the day at 17,678.70, and the S&P 500 closed at 2,057.09, up 0.26%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 825.01, up 0.45%, with the index also advancing 9.36% in the previous three months. Register for your complimentary reports at the links given below.
BLUE: 90.70 (+0.93), RNN: 0.75 (+0.01), NBIX: 37.22 (+0.27), ACHN: 10.89 (-0.20), ARRY: 8.05 (+0.08)
Major Street Movers: Special Research on D.R. Horton, MeadWestvaco, Ocwen, Microsoft and Array
PR Newswire - Tue Jan 27, 7:00AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including D.R. Horton (NYSE: DHI), MeadWestvaco (NYSE: MWV), Ocwen (NYSE: OCN), Microsoft (NASDAQ: MSFT), and Array (NASDAQ: ARRY). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
DHI: 27.19 (-0.15), OCN: 9.10 (+0.09), MWV: 53.91 (+0.59), MSFT: 43.87 (+0.78), ARRY: 8.05 (+0.08)
Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2015 On February 3, 2015
PR Newswire - Mon Jan 26, 2:00PM CST
Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the second quarter of fiscal 2015 and hold a conference call to discuss those results on Tuesday, February 3, 2015. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.
ARRY: 8.05 (+0.08), NVS: 102.20 (-0.17)
After Yesterday's Rally of 40.79% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Jan 23, 3:48PM CST
Array Biopharma (NASDAQ:ARRY) traded in a range yesterday that spanned from a low of $5.24 to a high of $7.58. Yesterday, the shares gained 40.8%, which took the trading range above the 3-day high of $5.07 on volume of 35.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARRY: 8.05 (+0.08)
How to Trade the Market's Most-Active Stocks: UPS, Avon and More
at The Street - Fri Jan 23, 12:47PM CST
Here's how to trade some of the most active stocks on the market today.
AVP: 9.08 (+0.39), FXCM: 2.21 (-0.01), UPS: 101.79 (+0.38), ARRY: 8.05 (+0.08)
Oncolytics Seeks Orphan Drug Status for Reolysin in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:59PM CST
Oncolytics Biotech Inc. (ONCY) announced that it has submitted an application to FDA for obtaining orphan drug designation for Reolysin for the treatment of high-grade gliomas (HGG) in pediatric patients.
AGN: 229.49 (+1.87), BIIB: 391.66 (-0.45), ONCY: 0.51 (+0.02), ARRY: 8.05 (+0.08)
Why Array BioPharma Inc. Shares Skyrocketed 51% in January
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 06, 6:35AM CST
ARRY data by YCharts What: Shares of Array BioPharma , a biopharmaceutical company that's focused on developing novel drugs to fight cancer, skyrocketed by 51% in January, based on data from S&P Capital IQ , after announcing a pipeline...
NVS: 102.20 (-0.17), ARRY: 8.05 (+0.08)
Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
PR Newswire - Thu Feb 05, 11:30AM CST
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Leerink Swann Healthcare Conference in New York. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
ARRY: 8.05 (+0.08)
Array BioPharma's (ARRY) CEO Ron Squarer on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 03, 3:25PM CST
ARRY: 8.05 (+0.08)
Array BioPharma (ARRY) Q2 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Feb 03, 7:55AM CST
ARRY: 8.05 (+0.08)
Array BioPharma beats by $0.12, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 7:02AM CST
ARRY: 8.05 (+0.08)
Array Biopharma Reports Financial Results For The Second Quarter Of Fiscal 2015
PR Newswire - Tue Feb 03, 7:00AM CST
Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the second quarter of its fiscal year ending June 30, 2015.
ARRY: 8.05 (+0.08), NVS: 102.20 (-0.17)
Notable earnings before Tuesday’s open
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 4:30PM CST
CEVA: 19.65 (+0.04), HCLP: 37.88 (+0.99), PNR: 66.87 (+1.09), AET: 96.12 (-0.96), HW: 15.96 (+0.10), UPS: 101.79 (+0.38), NOV: 53.36 (+0.80), JLL: 161.15 (+0.18), ST: 52.50 (+0.01), LYB: 89.99 (+0.19), ACI: 1.19 (+0.02), R: 93.92 (+0.41), TECH: 94.61 (+1.83), SPR: 49.35 (+0.47), BP: 41.93 (+0.59), NYT: 14.45 (+0.28), WDR: 49.94 (+0.15), HRC: 46.88 (+0.14), MNK: 115.01 (+2.51), SC: 22.11 (+0.38), CHD: 84.03 (+0.67), ETN: 72.55 (+0.90), BHE: 22.89 (+0.03), ARG: 115.27 (+1.28), AGCO: 49.78 (+0.97), EMR: 58.68 (+0.08), GLPI: 33.57 (-0.56), CNC: 118.18 (-0.01), HCA: 68.54 (-0.48), MHO: 21.20 (-0.27), CARB: 14.96 (+0.07), AXE: 76.07 (+0.44), IMS: 25.68 (+0.22), GCI: 34.77 (-0.07), LPT: 39.14 (-0.05), CBR: 4.05 (+0.04), ARRY: 8.05 (+0.08), AN: 63.70 (+0.23)
Uptrend Call Working As Array Biopharma Stock Rises 93.5% (ARRY)
Comtex SmarTrend(R) - Mon Feb 02, 9:09AM CST
SmarTrend identified an Uptrend for Array Biopharma (NASDAQ:ARRY) on October 28th, 2014 at $3.71. In approximately 3 months, Array Biopharma has returned 93.52% as of today's recent price of $7.17.
ARRY: 8.05 (+0.08)
'Mad Money' Lightning Round: Alliant Techsystems Is Fabulous
at The Street - Fri Jan 30, 5:00AM CST
Cramer prefers Garmin to Trimble Navigation and recommends Kohlberg Kravis Roberts and Blackstone Group.
LMT: 196.95 (-0.53), BX: 37.40 (+0.49), TRMB: 26.86 (-0.40), NOC: 167.14 (-0.15), GRMN: 55.93 (+0.02), PPC: 26.75 (+0.77), JDSU: 13.26 (+0.23), TSN: 40.70 (-0.09), KKR: 24.42 (+0.06), ATK: 140.03 (+0.78), ARRY: 8.05 (+0.08)
Defense Stocks Are Fabulous - Cramer's Lightning Round (1/29/15)
SA Editor Mohit Manghnani - Seeking Alpha - Fri Jan 30, 4:30AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, January 29. Bullish Calls: Trimble Navigation (NASDAQ: TRMB ): "I do prefer Garmin (NASDAQ: GRMN ) if you want to be in that game." KKR...
LMT: 196.95 (-0.53), BX: 37.40 (+0.49), TRMB: 26.86 (-0.40), MDCO: 29.79 (+0.91), NOC: 167.14 (-0.15), GRMN: 55.93 (+0.02), JDSU: 13.26 (+0.23), PPC: 26.75 (+0.77), TSN: 40.70 (-0.09), KKR: 24.42 (+0.06), ATK: 140.03 (+0.78), MTW: 21.86 (+0.34), ARRY: 8.05 (+0.08)
Jim Cramer's 'Mad Money' Recap: The Bears Retreat and the Market Celebrates
at The Street - Thu Jan 29, 7:19PM CST
Today was a terrific snap-back rally, a day when the bears retreated and calmer heads could take advantage of all the positives that go unappreciated on most days, Cramer says.
LMT: 196.95 (-0.53), BX: 37.40 (+0.49), FB: 75.74 (-0.49), NOC: 167.14 (-0.15), GRMN: 55.93 (+0.02), TSN: 40.70 (-0.09), KKR: 24.42 (+0.06), ATK: 140.03 (+0.78), BA: 149.73 (+1.64), CLB: 112.18 (+3.65), SBUX: 91.58 (-0.24), RDUS: 50.37 (+0.63), TRMB: 26.86 (-0.40), PHM: 22.89 (+0.02), PPC: 26.75 (+0.77), JDSU: 13.26 (+0.23), MCD: 95.65 (+0.56), ARRY: 8.05 (+0.08)
Earnings Peek: Array BioPharma Has A Lot Going On, And A Lot Of Money
Clinically Sound Investor - at Seeking Alpha - Wed Jan 28, 9:18AM CST
ARRY: 8.05 (+0.08)
Does This 50% Price Target Hike For Array BioPharma Inc. Make Sense?
Sean Williams, The Motley Fool - Motley Fool - Tue Jan 27, 8:51AM CST
What: Shares of Array BioPharma , a biopharmaceutical company focused on developing novel small molecule cancer drugs, surged just shy of 10% on Monday following a hefty price target hike from brokerage firm Stifel Nicolaus. So what: Stifel...
NVS: 102.20 (-0.17), ARRY: 8.05 (+0.08)
Array BioPharma (ARRY) Jumps: Stock Adds 9.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 27, 7:51AM CST
Array BioPharma, Inc. (ARRY) was a big mover last session, as the company saw its shares rise by almost 10% on the day.
AMAG: 41.49 (+0.23), ARRY: 8.05 (+0.08)
Biotech Stocks Technical Analysis - Achillion Pharma, Array BioPharma, Rexahn Pharma, Neurocrine Biosciences, and Bluebird Bio
PR Newswire - Tue Jan 27, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Array BioPharma Inc. (NASDAQ: ARRY), Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Bluebird Bio Inc. (NASDAQ: BLUE). Free research report on Achillion Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=Achillion...amp;s=ACHN. On Monday, January 26, 2015, the NASDAQ Composite ended at 4,771.76, up 0.29%, the Dow Jones Industrial Average advanced 0.03%, to finish the day at 17,678.70, and the S&P 500 closed at 2,057.09, up 0.26%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 825.01, up 0.45%, with the index also advancing 9.36% in the previous three months. Register for your complimentary reports at the links given below.
BLUE: 90.70 (+0.93), RNN: 0.75 (+0.01), NBIX: 37.22 (+0.27), ACHN: 10.89 (-0.20), ARRY: 8.05 (+0.08)
Major Street Movers: Special Research on D.R. Horton, MeadWestvaco, Ocwen, Microsoft and Array
PR Newswire - Tue Jan 27, 7:00AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including D.R. Horton (NYSE: DHI), MeadWestvaco (NYSE: MWV), Ocwen (NYSE: OCN), Microsoft (NASDAQ: MSFT), and Array (NASDAQ: ARRY). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
DHI: 27.19 (-0.15), OCN: 9.10 (+0.09), MWV: 53.91 (+0.59), MSFT: 43.87 (+0.78), ARRY: 8.05 (+0.08)
Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2015 On February 3, 2015
PR Newswire - Mon Jan 26, 2:00PM CST
Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the second quarter of fiscal 2015 and hold a conference call to discuss those results on Tuesday, February 3, 2015. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.
ARRY: 8.05 (+0.08), NVS: 102.20 (-0.17)
After Yesterday's Rally of 40.79% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Jan 23, 3:48PM CST
Array Biopharma (NASDAQ:ARRY) traded in a range yesterday that spanned from a low of $5.24 to a high of $7.58. Yesterday, the shares gained 40.8%, which took the trading range above the 3-day high of $5.07 on volume of 35.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARRY: 8.05 (+0.08)
How to Trade the Market's Most-Active Stocks: UPS, Avon and More
at The Street - Fri Jan 23, 12:47PM CST
Here's how to trade some of the most active stocks on the market today.
AVP: 9.08 (+0.39), FXCM: 2.21 (-0.01), UPS: 101.79 (+0.38), ARRY: 8.05 (+0.08)
